Current and future treatment approaches for neuromyelitis optica

Therapeutic Advances in Neurological Disorders

Volumn 4, Issue 2, 2011, Pages 111-121

  Collongues, Nicolas ^a   Seze, Jerome ^a  

^a HÔPITAL CIVIL   (France)

Author keywords

CD20; complement; immunosuppressive drug; neuromyelitis optica

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

FOLLOW UP; HUMAN; MYELOOPTIC NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REVIEW;

EID: 79955985808     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285611398939     Document Type: Review

References (65)

1. Agostoni A. Aygoren-Pursun E. Binkley K.E. Blanch A. Bork K. Bouillet L. et al (2004) Hereditary and acquired angioedema: problems and progress: proceedings of the third C 1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114(3 Suppl): S51–S131.
2. Allison A.C. Eugui E.M. (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47: 85–118.
3. Arabshahi B. Pollock A.N. Sherry D.D. Albert D.A. Kreiger P.A. Pessler F. (2006) Devic disease in a child with primary Sjogren syndrome. J Child Neurol 21: 285–286.
4. Axtell R.C. de Jong B.A. Boniface K. van der Voort L.F. Bhat R. de Sarno P. et al (2010) T helper type 1 and 17 cells determine efficacy of interferon‐beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16: 406–412.
5. Bakker J. Metz L. (2004) Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 31: 265–267.
6. Bergamaschi R. Uggetti C. Tonietti S. Egitto M.G. Cosi V. (2003) A case of relapsing neuromyelitis optica treated with glatiramer acetate. J Neurol 250: 359–361.
7. Birnbaum J. Kerr D. (2008) Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nat Clin Pract Rheumatol 4: 381–386.
8. Bonnan M. Valentino R. Olindo S. Mehdaoui H. Smadja D. Cabre P. (2009) Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 15: 487–492.
9. Bonnet F. Mercie P. Morlat P. Hocke C. Vergnes C. Ellie E. et al (1999) Devic's neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus. Lupus 8: 244–247.
10. Boye J. Elter T. Engert A. (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14: 520–535.
11. Cabre P. Gonzalez-Quevedo A. Bonnan M. Saiz A. Olindo S. Graus F. et al (2009) Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry 80: 1162–1164.
12. Capobianco M. Malucchi S. di Sapio A. Gilli F. Sala A. Bottero R. et al (2007) Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci 28: 209–211.
13. Collongues N. Marignier R. Zephir H. Papeix C. Blanc F. Ritleng C. et al (2010) Neuromyelitis optica in France: A multicenter study of 125 patients. Neurology 74: 736–742.
14. Cree B.A. Lamb S. Morgan K. Chen A. Waubant E. Genain C. (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64: 1270–1272.
15. Dass S. Rawstron A.C. Vital E.M. Henshaw K. McGonagle D. Emery P. (2008) Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 58: 2993–2999.
16. Davis A.E. III Mejia P. Lu F. (2008) Biological activities of C 1 inhibitor. Mol Immunol 45: 4057–4063.
17. de Jonge M.E. Huitema A.D. Rodenhuis S. Beijnen J.H. (2005) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44: 1135–1164.
18. de Seze J. Lebrun C. Stojkovic T. Ferriby D. Chatel M. Vermersch P. (2003) Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 9: 521–525.
19. Edan G. Miller D. Clanet M. Confavreux C. Lyon-Caen O. Lubetzki C. et al (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62: 112–118.
20. Ehninger G. Schuler U. Proksch B. Zeller K.P. Blanz J. (1990) Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 18: 365–380.
21. Fink K. Lang K.S. Manjarrez-Orduno N. Junt T. Senn B.M. Holdener M. et al (2006) Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses. Eur J Immunol 36: 2094–2105.
22. Gartzen K. Limmroth V. Putzki N. (2007) Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. Eur J Neurol 14: e12–e13.
23. Greenberg B.M. Thomas K.P. Krishnan C. Kaplin A.I. Calabresi P.A. Kerr D.A. (2007) Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 68: 1614–1617.
24. Gronseth G. French J. (2008) Practice parameters and technology assessments: what they are, what they are not, and why you should care. Neurology 71: 1639–1643.
25. Halstead S.K. Zitman F.M. Humphreys P.D. Greenshields K. Verschuuren J.J. Jacobs B.C. et al (2008) Eculizumab prevents anti-ganglioside antibody‐mediated neuropathy in a murine model. Brain 131: 1197–1208.
26. Hinson S.R. Roemer S.F. Lucchinetti C.F. Fryer J.P. Kryzer T.J. Chamberlain J.L. et al (2008) Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 205: 2473–2481.
27. Jacob A. Matiello M. Weinshenker B.G. Wingerchuk D.M. Lucchinetti C. Shuster E. et al (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66: 1128–1133.
28. Jacob A. Weinshenker B.G. Violich I. McLinskey N. Krupp L. Fox R.J. et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65: 1443–1448.
29. Jarius S. Aboul-Enein F. Waters P. Kuenz B. Hauser A. Berger T. et al (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131: 3072–3080.
30. Krumbholz M. Faber H. Steinmeyer F. Hoffmann L.A. Kumpfel T. Pellkofer H. et al (2008) Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131: 1455–1463.
31. Kumlien G. Ullstrom L. Losvall A. Persson L.G. Tyden G. (2006) Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies. Transfusion 46: 1568–1575.
32. Lennon V.A. Kryzer T.J. Pittock S.J. Verkman A.S. Hinson S.R. (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473–477.
33. Lennon V.A. Wingerchuk D.M. Kryzer T.J. Pittock S.J. Lucchinetti C.F. Fujihara K. et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106–2112.
34. Mandler R.N. Ahmed W. Dencoff J.E. (1998) Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51: 1219–1220.
35. McDaneld L.M. Fields J.D. Bourdette D.N. Bhardwaj A. (2010) Immunomodulatory therapies in neurologic critical care. Neurocrit Care 12: 132–143.
36. Miyamoto K. Kusunoki S. (2009) Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 13: 505–508.
37. Mok C.C. To C.H. Mak A. Poon W.L. (2008) Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol 35: 172–174.
38. Moreh E. Gartsman I. Karussis D. Rund D. Hiller N. Meiner Z. (2008) Seronegative neuromyelitis optica: improvement following lymphocytapheresis treatment. Mult Scler 14: 860–861.
39. Nakashima, I., Takahashi, T., Cree, B.A., Suzuki, C., Fujihara, K., Itoyama, Y. et al. (2010) Anti-Aquaporin 4 Antibodies Increase Transiently after Rituximab Treatment in Neuromyelitis Optica with an Association of B Cell Activating Factor. American Academy of Neurology, Poster P02.191.
40. Nasir S. Kerr D.A. Birnbaum J. (2009) Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus. Arch Neurol 66: 1160–1163.
41. Neuhaus O. Kieseier B.C. Hartung H.P. (2004) Mechanisms of mitoxantrone in multiple sclerosis–what is known? J Neurol Sci 223: 25–27.
42. Nielsen O.H. Vainer B. Rask-Madsen J. (2001) Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 15: 1699–1708.
43. Noseworthy J.H. O'Brien P.C. Petterson T.M. Weis J. Stevens L. Peterson W.K. et al (2001) A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56: 1514–1522.
44. Palace J. Leite M.I. Nairne A. Vincent A. (2010) Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 67: 1016–1017.
45. Papeix C. Vidal J.S. de Seze J. Pierrot-Deseilligny C. Tourbah A. Stankoff B. et al (2007) Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 13: 256–259.
46. Pittock S.J. Weinshenker B.G. Lucchinetti C.F. Wingerchuk D.M. Corboy J.R. Lennon V.A. (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63: 964–968.
47. Rother R.P. Rollins S.A. Mojcik C.F. Brodsky R.A. Bell L. (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25: 1256–1264.
48. Rus H. Cudrici C. Niculescu F. Shin M.L. (2006) Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. J Neuroimmunol 180: 9–16.
49. Saida T. Tashiro K. Itoyama Y. Sato T. Ohashi Y. Zhao Z. (2005) Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 64: 621–630.
50. Sanchez-Carteyron A. Alarcia R. Ara J.R. Martin J. (2010) Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica. Neurology 74: 1471–1473.
51. Sellner, J., Boggild, M., Clanet, M., Hintzen, R.Q., Illes, Z., Montalban, X. et al. (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol, in press.
52. Shimizu Y. Yokoyama K. Misu T. Takahashi T. Fujihara K. Kikuchi S. et al (2008) Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 255: 305–307.
53. Stewart D.J. Green R.M. Mikhael N.Z. Montpetit V. Thibault M. Maroun J.A. (1986) Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep 70: 1255–1261.
54. Tanaka M. Tanaka K. Komori M. (2009) Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol 62: 167–170.
55. Uzawa A. Mori M. Hayakawa S. Masuda S. Kuwabara S. (2010) Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 17: 672–676.
56. van Meerten T. Hagenbeek A. (2010) CD20-targeted therapy: the next generation of antibodies. Semin Hematol 47: 199–210.
57. Vital E.M. Dass S. Rawstron A.C. Buch M.H. Goeb V. Henshaw K. et al (2010) Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 62: 1273–1279.
58. Wagner E. Frank M.M. (2010) Therapeutic potential of complement modulation. Nat Rev Drug Discov 9: 43–56.
59. Warabi Y. Matsumoto Y. Hayashi H. (2007) Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 252: 57–61.
60. Watanabe S. Nakashima I. Misu T. Miyazawa I. Shiga Y. Fujihara K. et al (2007) Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13: 128–132.
61. Weiner H.L. Cohen J.A. (2002) Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 8: 142–154.
62. Weinshenker B.G. O'Brien P.C. Petterson T.M. Noseworthy J.H. Lucchinetti C.F. Dodick D.W. et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46: 878–886.
63. Weinstock-Guttman B. Ramanathan M. Lincoff N. Napoli S.Q. Sharma J. Feichter J. et al (2006) Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 63: 957–963.
64. Wingerchuk D.M. Hogancamp W.F. O'Brien P.C. Weinshenker B.G. (1999) The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53: 1107–1114.
65. Wingerchuk D.M. Lennon V.A. Pittock S.J. Lucchinetti C.F. Weinshenker B.G. (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485–1489.